ROS1 and non-small cell lung carcinoma: Crizotinib, endorsed by the U.S. Food and Drug Administration (FDA) in 2016, was the inaugural tyrosine kinase inhibitor (TKI) approved for first-line treatment of ROS1 fusion-positive NSCLC (12, 13).